Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Laura on +44 (0) 1494 818026 or laura@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Laura Marsh
Recruitment Consultant
laura@zenopa.com
+44 (0) 1494 818026

Testimonials
From first conversation right through to negotiations I would summarise your involvement in the process as (i) highly professional (ii) consultative and (iii) thoroughly supportive.
Ben , 2013

Ipsen reports strong performance in first half of 2010

1 September 2010 00:00 in Pharmaceutical Company Financials


Ipsen has hailed the strength of its financial performance in 2010 on the back of strong results in its report for the first half of the year.

The pharmaceutical company saw a 6.3 per cent year-on-year increase in consolidated group sales during the six months to 553.9 million euros (460.5 million pounds), while remaining on target to achieve all of its financial objectives for the year.

Among the measures on which the company made progress were achieving growth in specialty care product sales, profits and earnings, while dynamic drug sales were up by six per cent year-on-year.

Jean-Luc Belingard, chairman and chief executive officer of Ipsen, also noted the company's new partnership with Inspiration Biopharmaceuticals, which will provide the firm with a new portfolio of clotting factor products.

He added: "Above and beyond the transaction with Inspiration and its diversified international presence, the group continues to secure its future by actively developing its rich research and development pipeline."

Earlier this year, Ipsen posted data from a phase III clinical trial of its type 2 diabetes drug taspoglutide, demonstrating its efficacy in reducing glycosylated haemoglobin levels and body weight.ADNFCR-8000103-ID-800046969-ADNFCR

Other news stories from 01/09/2010

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd